(SCNI)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Scinai Immunotherapeutics Ltd., bioterapiya kompaniyasi, Isroilda yuqumli va otoimmunitetli kasalliklarni davolash uchun yallig'lanish va immunologik biologik mahsulotlarni ishlab chiqish, ishlab chiqarish va tijoratlashtirishga qaratilgan. U tibbiy ehtiyojlari qondirilmagan kasalliklarga qarshi nanoo'lchamdagi VHH antitelalarini (nanoAbs) va pemfigus, Stiven Jonsson sindromi va toksik epidermal nekrolizni davolash uchun monoklonal antitelani ishlab chiqadi. Kompaniya, shuningdek, biotexnologiya kompaniyalari uchun shartnoma asosida ishlab chiqish va ishlab chiqarish xizmatlarini taqdim etadi. COVID-19 ga qarshi nanoo'lchamdagi antitelani ishlab chiqish va tijoratlashtirish bo'yicha Max Planck Jamiyati va Getyingen Universitet tibbiyot markazi bilan litsenziyalash va hamkorlik shartnomasiga ega. Kompaniya avval BiondVax Pharmaceuticals Ltd. nomi bilan tanilgan va 2023-yil sentyabr oyida Scinai Immunotherapeutics Ltd. nomiga o'zgargan. Scinai Immunotherapeutics Ltd. 2003-yilda tashkil etilgan va Isroilning Quddus shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Naama Adi Hen | Head of Quality Asurance |
| Gal Ron | Head of HR |
| Merav Kamensky | Head of Quality Control & GMP Analytics |
| Mr. Amir Reichman M.B.A., M.Sc. | CEO & Director |
| Mr. Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Tehila Sonnenfeld | Head of Manufacturing |
| Sana | Turi | Hujjat |
|---|---|---|
| 2025-12-23 | 6-K | ea0270793-6k_scinai.htm |
| 2025-12-02 | 6-K | ea0268089-6k_scinai.htm |
| 2025-11-13 | 6-K | ea0265488-6k_scinai.htm |
| 2025-11-12 | S-8 | ea0264993-s8_scinai.htm |
| 2025-09-29 | CORRESP | filename1.htm |
| 2025-09-22 | F-1 | ea0258179-f1_scinai.htm |
| 2025-09-11 | 6-K | ea0256954-6k_scinai.htm |
| 2025-09-04 | POS AM | ea0255998-posam2_scinai.htm |
| 2025-09-02 | 6-K | ea0255452-6k_scinai.htm |
| 2025-06-12 | 6-K | ea0245554-6k_scinai.htm |